我们能否做得更好，超越多巴酚丁胺？
Can we do better than dobutamine?
机构信息
University of Chicago, Chicago, IL 60637, USA.
出版信息
Circ Res. 2013 Aug 2;113(4):355-7. doi: 10.1161/CIRCRESAHA.113.302000.
Abstract
The development of dobutamine, an infusible inotropic drug for heart failure, was first described in 1975. Although this sympathomimetic was designed to increase cardiac output, it is far from ideal as a longterm safe strategy. New drugs for acute heart failure are needed, and to develop new approaches will require diverse expertise and resources.
摘要
多巴酚丁胺是一种用于心力衰竭的可输注正性肌力药物，其研发最早可追溯至 1975 年。虽然这种拟交感神经药物旨在增加心输出量，但它远非长期安全策略的理想选择。急性心力衰竭需要新的药物，而开发新方法将需要多样化的专业知识和资源。
相似文献
1
Can we do better than dobutamine?我们能否做得更好，超越多巴酚丁胺？
Circ Res. 2013 Aug 2;113(4):355-7. doi: 10.1161/CIRCRESAHA.113.302000.
2
Short-term use of intravenous milrinone for heart failure.
Am J Cardiol. 1995 Apr 15;75(12):822-6. doi: 10.1016/s0002-9149(99)80420-2.
3
Dobutamine: a new synthetic cardioactive sympathetic amine.
N Engl J Med. 1979 Jan 4;300(1):17-22. doi: 10.1056/NEJM197901043000105.
4
5
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.左西孟旦用于低心排血量心力衰竭患者：来自LIDO试验的经验教训。
Ital Heart J. 2003 May;4 Suppl 2:34S-38S.
6
Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.米力农和多巴酚丁胺用于严重心力衰竭：不同的血流动力学效应及个体患者反应性
Circulation. 1986 Mar;73(3 Pt 2):III175-83.
7
Transient dobutamine-mediated pulsus alternans.短暂性多巴酚丁胺介导的交替脉
Can J Cardiol. 2001 Feb;17(2):203-5.
8
New catecholamines in clinical cardiovascular medicine.
Kardiol Pol. 1980;23(9):721-5.
9
Positive inotropic agents in congestive heart failure.
Coron Artery Dis. 1993 Jan;4(1):44-52. doi: 10.1097/00019501-199301000-00006.
10
Comparative vasoactive therapy for heart failure.心力衰竭的比较性血管活性治疗
Am J Cardiol. 1985 Jul 22;56(3):19B-24B. doi: 10.1016/0002-9149(85)91191-9.
引用本文的文献
1
The effect of dobutamine treatment on salvage of digital replantation and revascularization.多巴酚丁胺治疗对断指再植和血运重建的挽救作用。
Eur J Trauma Emerg Surg. 2023 Oct;49(5):2113-2120. doi: 10.1007/s00068-023-02312-x. Epub 2023 Jun 27.
2
The apelinergic system as an alternative to catecholamines in low-output septic shock.阿片肽能系统作为低排出量脓毒性休克儿茶酚胺的替代物。
Crit Care. 2018 Jan 19;22(1):10. doi: 10.1186/s13054-018-1942-z.
本文引用的文献
1
Placing a value on new technologies.评估新技术的价值。
Circulation. 2013 Jun 18;127(24):2375-7. doi: 10.1161/CIRCULATIONAHA.113.003196. Epub 2013 May 22.
2
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association.执行摘要：《2013年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2013 Jan 1;127(1):143-52. doi: 10.1161/CIR.0b013e318282ab8f.
3
Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease.正性肌力药和血管升压药：心血管疾病中的生理学及临床应用综述
Circulation. 2008 Sep 2;118(10):1047-56. doi: 10.1161/CIRCULATIONAHA.107.728840.
4
The price of innovation: new estimates of drug development costs.创新的代价：药物研发成本的新估计
J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1.
5
Inotropic therapy for heart failure: an evidence-based approach.心力衰竭的正性肌力治疗：循证医学方法
Am Heart J. 2001 Sep;142(3):393-401. doi: 10.1067/mhj.2001.117606.
6
Differentiation of receptor systems activated by sympathomimetic amines.拟交感胺激活的受体系统的分化
Nature. 1967 May 6;214(5088):597-8. doi: 10.1038/214597a0.
7
Stereospecific (3H)(minus)-alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase.立体特异性（3H）（负）-阿普洛尔结合位点、β-肾上腺素能受体与腺苷酸环化酶
Biochem Biophys Res Commun. 1974 Sep 23;60(2):703-9. doi: 10.1016/0006-291x(74)90297-6.
8
Adrenergic receptors: a personal and practical view.肾上腺素能受体：个人见解与实用观点
Perspect Biol Med. 1973 Autumn;17(1):119-22. doi: 10.1353/pbm.1973.0047.
9
Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.多巴酚丁胺：一种新型儿茶酚胺的研发，用于选择性增强心肌收缩力。
Circ Res. 1975 Jan;36(1):185-96. doi: 10.1161/01.res.36.1.185.
10
Alpha-adrenergic receptor identification by (3H)dihydroergocryptine binding.通过（3H）二氢麦角隐亭结合鉴定α-肾上腺素能受体。
Science. 1976 May 21;192(4241):791-3. doi: 10.1126/science.4894.
Zotero 插件